Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.

Third Quarter 2014 Financial Results

Genmab reported its Third Quarter 2014 financial results and held a conference call on November 5. Click the following links to access the archived call: Listen to the webcast/podcast; download the slide presentation.

Genmab Opens Doors to Innovation

Genmab is inviting researchers in academia and industry to experience the full power of the DuoBody® platform for bispecific antibody research and drug development. Explore the possibilities via our recently published Perspective in the journal mAbs and the renewed Open Innovation section on


Genmab to Host Post-ASH Seminar

On December 9, 2014 from 3:30 PM to 5:30 PM EST (9:30 PM to 11:30 PM CET) Genmab will host a webcast of its Post-ASH Seminar, which will provide an update on the Company's progress during 2014, including data from studies with the Company's antibodies presented at the 2014 American Society of Hematology (ASH) Annual Meeting, progress with Genmab's proprietary technologies and expected performance milestones for 2015. Webcast details will follow.

Latest news


  • At the heart of Genmab is a deep desire to improve the quality of life for cancer patients.
  • Click here to watch our video about our fight against cancer.


Stock Price as of 11/21/2014 12:00 AM (CET)

  • Share Price DKK 280.50
  • Change (in DKK) 1.80
  • Volume 131073

Stock Information